At Memorial Sloan Kettering Cancer Center, our world-renowned cancer researchers, oncologists, clinicians, and scientists are constantly advancing our knowledge about cancer. Our discoveries are improving treatment and care for patients here and all over the world. On this page, you will find news & information about our latest groundbreaking cancer science, exceptional patient care and the dedicated professionals who make it all happen.
For Journalists
Connect with us to reach MSK experts for media inquiries and for story ideas.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the Northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by U.S. News & World Report in its annual Best Hospitals listing.
Over the last seven and a half decades, researchers at the Sloan Kettering Institute have made important contributions to the fundamental understanding of human biology, as well as driven practice-changing innovations in the treatment of cancer.
Nick Kroll, Brett Goldstein, Zarna Garg, Hasan Minhaj, Bridget Everett, and special guests took the stage for a one-night-only event, raising $2.5 million to fuel Memorial Sloan Kettering Cancer Center’s mission of ending cancer for life
Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer discovery at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, in San Diego, California.
Lonny Yarmus, DO, MBA, has been appointed Head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Dr. Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.
The FDA has approved the targeted therapy datopotamab deruxtecan (Datroway® or Dato-DXd) for triple-negative breast cancer based on clinical research led by MSK.
MSK scientists are part of an international consortium working to determine the biological functions of the roughly 20,000 protein-coding genes in the human genome.
After a cancer diagnosis, one of the first and toughest decisions people face is how much to share in the workplace. Read more about working with cancer — and how MSK offers guidance and support.
Learn how MSK is making clinical trials more accessible through innovative new approaches that bring care to people's homes and make participating possible even for people who live far from MSK.
Every year, thousands of people travel from across the country and around the world in search of hope at MSK. Learn how MSK supports patients far from home.
Cancer Straight Talk brings together national experts and cancer patients to have straightforward, evidence-based conversations. Its mission is to educate and empower cancer patients and their families to make the right decisions and live happier, healthier lives.
